| http://purl.uniprot.org/citations/21767516 | http://www.w3.org/1999/02/22-rdf-syntax-ns#type | http://purl.uniprot.org/core/Journal_Citation |
| http://purl.uniprot.org/citations/21767516 | http://www.w3.org/2000/01/rdf-schema#comment | "Patients with acute myeloid leukemia (AML) and internal tandem duplication of FMS-like tyrosine kinase receptor-3 gene (FLT3-ITD) mutation have poor prognoses and are often treated with allogeneic hematopoietic stem cell transplantation (HSCT). Sorafenib, an inhibitor of multiple kinases including FLT3, has shown promising activity in FLT3-ITD-positive AML. We treated 16 patients with FLT3-ITD-positive AML who relapsed after HSCT with sorafenib alone (n = 8) or in combination with cytotoxic chemotherapy (n = 8). The number of circulating blasts decreased in 80% of cases, but none of the patients achieved complete remission (CR); 3 achieved partial remission. Two patients were bridged to a second transplantation but both relapsed within 3 months of the transplantation. Median overall survival (OS) was 83 days, with none surviving more than a year. Sorafenib is not effective in the treatment of FLT3-ITD-positive AML relapsing after HSCT. Preventive strategies after HSCT may be more suitable for these high-risk patients."xsd:string |
| http://purl.uniprot.org/citations/21767516 | http://purl.org/dc/terms/identifier | "doi:10.1016/j.bbmt.2011.07.011"xsd:string |
| http://purl.uniprot.org/citations/21767516 | http://purl.uniprot.org/core/author | "Chen J."xsd:string |
| http://purl.uniprot.org/citations/21767516 | http://purl.uniprot.org/core/author | "Sharma M."xsd:string |
| http://purl.uniprot.org/citations/21767516 | http://purl.uniprot.org/core/author | "Andreeff M."xsd:string |
| http://purl.uniprot.org/citations/21767516 | http://purl.uniprot.org/core/author | "Bashir Q."xsd:string |
| http://purl.uniprot.org/citations/21767516 | http://purl.uniprot.org/core/author | "de Lima M."xsd:string |
| http://purl.uniprot.org/citations/21767516 | http://purl.uniprot.org/core/author | "Cortes J."xsd:string |
| http://purl.uniprot.org/citations/21767516 | http://purl.uniprot.org/core/author | "Kebriaei P."xsd:string |
| http://purl.uniprot.org/citations/21767516 | http://purl.uniprot.org/core/author | "Kantarjian H."xsd:string |
| http://purl.uniprot.org/citations/21767516 | http://purl.uniprot.org/core/author | "Konopleva M."xsd:string |
| http://purl.uniprot.org/citations/21767516 | http://purl.uniprot.org/core/author | "Ravandi F."xsd:string |
| http://purl.uniprot.org/citations/21767516 | http://purl.uniprot.org/core/author | "McCue D."xsd:string |
| http://purl.uniprot.org/citations/21767516 | http://purl.uniprot.org/core/author | "Champlin R.E."xsd:string |
| http://purl.uniprot.org/citations/21767516 | http://purl.uniprot.org/core/author | "Giralt S."xsd:string |
| http://purl.uniprot.org/citations/21767516 | http://purl.uniprot.org/core/author | "Bayraktar U.D."xsd:string |
| http://purl.uniprot.org/citations/21767516 | http://purl.uniprot.org/core/author | "Chiattone A."xsd:string |
| http://purl.uniprot.org/citations/21767516 | http://purl.uniprot.org/core/author | "Qazilbash M."xsd:string |
| http://purl.uniprot.org/citations/21767516 | http://purl.uniprot.org/core/date | "2011"xsd:gYear |
| http://purl.uniprot.org/citations/21767516 | http://purl.uniprot.org/core/name | "Biol Blood Marrow Transplant"xsd:string |
| http://purl.uniprot.org/citations/21767516 | http://purl.uniprot.org/core/pages | "1874-1877"xsd:string |
| http://purl.uniprot.org/citations/21767516 | http://purl.uniprot.org/core/title | "Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib."xsd:string |
| http://purl.uniprot.org/citations/21767516 | http://purl.uniprot.org/core/volume | "17"xsd:string |
| http://purl.uniprot.org/citations/21767516 | http://www.w3.org/2004/02/skos/core#exactMatch | http://purl.uniprot.org/pubmed/21767516 |